您的位置：首页 > 产品中心 > 501925-31-1， PNU-120596
PNU-120596
产品价格查看更多规格...
| 产品编号 | 包装单位 | 单价(元) | 国内现货 | 国外库存 | 询价单 |
| 3183880 | 5 MG | 1320 | |||
| 3183880 | 25 MG | 4890 |
产品别名
501925-31-1
PNU-120596
N-(5-Chloro-2,4-dimethoxyphenyl)-N′-(5-methyl-3-isoxazolyl)-urea
NSC 216666
结构式
基本信息
| Empirical Formula【经验(实验)分子式】 | C13H14ClN3O4 |
| Molecular weight | 311.72 |
| MDL number | MFCD00095313 |
| PubChem Substance ID【PubChem化学物质编号】 | 329819995 |
| NACRES | NA.77 |
| Biochem/physiol Actions【生化/生理作用】 | An allosteric modulator of α7 nicotinic receptors, N-(5-chloro-2,4-dimethoxyphenyl)-N′-(5-methyl-3-isoxazolyl)-urea (PNU-120596), causes conformational changes in the extracellular ligand binding domain similar to those caused by acetylcholinePNU-120596 is a positive allosteric modulator selective for the α7 nicotinic acetylcholine receptor. PNU-120596 produces no detectable change in currents mediated by α4β2, α3β4, α9α10 nAChRs. It increases channel mean open time, but does not affect ion selectivity. It does not bind at the agonist binding site, but induces conformational changes similar to the natural effector. |
| Features and Benefits【特点和优势】 | This compound was developed by Pfizer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here. |
产品性质
| Quality Level【质量水平】 | 100 |
| Assay【测定】 | ≥98% (HPLC) |
| color【颜色】 | white to off-white |
| solubility【溶解性】 | DMSO: >10 mg/mL |
| originator【创始人】 | Pfizer |
| storage temp.【储存温度】 | room temp |
| SMILES string | O=C(NC1=NOC(C)=C1)NC2=CC(Cl)=C(OC)C=C2OC |
| InChI | 1S/C13H14ClN3O4/c1-7-4-12(17-21-7)16-13(18)15-9-5-8(14)10(19-2)6-11(9)20-3/h4-6H,1-3H3,(H2,15,16,17,18) |
| InChI key | CEIIEALEIHQDBX-UHFFFAOYSA-N |
| packaging【包装】 | 5, 25 mg in glass bottle |
安全信息
| Storage Class Code【储存分类代码】 | 11 - Combustible Solids |
| WGK | WGK 3 |
